Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: COVID-19 Antigen, Antibody Tests By LuSys Labs Could Give Wrong Results, Shouldn’t Be Used

Tests might’ve been sold under names Luscient Diagnostics, Vivera Pharmaceuticals or EagleDx

Executive Summary

The US FDA on 11 January issued a safety alert that the diagnostics made by LuSys Laboratories could give false-positive or false-negative results. The agency has asked health care providers and others to stop using the tests.

You may also be interested in...



Stop Using E25Bio COVID-19 Antigen Tests, FDA Says

The US FDA is asking health care providers and the public to cease using the E25Bio COVID-19 Direct Antigen Rapid Test because the agency is concerned about the diagnostic giving false results. The FDA is also worried that people could injure themselves when self-collecting a sample from the nose or throat.

FDA Warns: Don’t Use CovClear, ImmunoPass COVID-19 Tests; High-Risk Class I Recall Underway

The US FDA said on 28 January that it’s worried about the potential for false-negative or false-positive results given from the diagnostics, which were made by Empowered Diagnostics. The company has recalled the tests because they weren’t authorized by the agency for use in the US.

Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot

In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT144932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel